Journal: Nature Communications

Article Title: A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy

doi: 10.1038/s41467-023-40996-2

Figure Lengend Snippet: a Microscopic images of RAW264.7 cells before and after treating with LPS and IFN-γ. Scale bars: 20 μm. b Representative flow cytometry plots of M1 phenotype (CD80 + CD86 + ) in RAW264.7 cells before and after treating with LPS and IFN-γ. Representative DLS results and (inset) TEM images of c MPNPs and d M1-MPNPs. Scale bars: 100 nm. e , f Average sizes and zeta potentials of various NPs. Data are presented as mean ± SD ( n = 3 independent experiments). g Representative western blots of CD86 and iNOS expression in different formulations. h The excitation-emission mapping of M1-MPNPs. For b – d , g , h , experiment was repeated three times independently with similar results. Source data are provided as a Source Data file.

Article Snippet: Antibodies used: Western blotting: Anti-CD86 (C-terminal) Polyclonal antibody (1:1000, Proteintech, Rabbit mAb, #26903-1-AP); Recombinant Anti-iNOS antibody (1:1000, Abcam, Rabbit mAb, #ab178945); CD47 (D3O7P) Rabbit mAb (1:1000, Cell Signaling Technology, #63000); Na,K-ATPase Antibody (1:1000, Cell Signaling Technology, #3010); Integrin alpha 4/CD49D (1:1000, Abcam, Rabbit mAb, #ab81280); Integrin beta 1 (1:1000, Abcam, Rabbit mAb, #ab52971).

Techniques: Flow Cytometry, Western Blot, Expressing

Journal: Nature Communications

Article Title: A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy

doi: 10.1038/s41467-023-40996-2

Figure Lengend Snippet: a Experimental outline showing the treatment steps and procedures for evaluating the therapeutic outcomes in 4T1 tumor-bearing mice. The “i.v.” represents “intravenous injection”. The illustration was created with BioRender.com. Plots of b tumor volume, c individual tumor volume, d tumor weight, and e body weight of the 4T1 tumor-bearing mice with various treatments. Data are presented as mean ± SD ( n = 5 mice). Statistical significance was determined using one-way ANOVA. f Representative H&E staining and TUNEL staining of tumor sections harvested from the mice receiving different treatments on day 14 ( n = 3 mice). Scale bars: 50 μm. Experiment was repeated three times independently with similar results. g Representative CLSM images showing ecto-CRT expression (red pseudocolor) on the tumor sections from the mice receiving various treatments. Scale bars: 50 μm. Experiment was repeated three times independently with similar results. h Quantitative data of the population of DC maturation (CD11c + CD80 + CD86 + ) in lymph nodes after various treatments. Data are presented as mean ± SD ( n = 3 mice). Statistical significance was determined using one-way ANOVA. i Quantitative data of the percentages of CD8 + T cells in tumor. Data are presented as mean ± SD ( n = 3 mice). Statistical significance was determined using one-way ANOVA. Source data are provided as a Source Data file.

Article Snippet: Antibodies used: Western blotting: Anti-CD86 (C-terminal) Polyclonal antibody (1:1000, Proteintech, Rabbit mAb, #26903-1-AP); Recombinant Anti-iNOS antibody (1:1000, Abcam, Rabbit mAb, #ab178945); CD47 (D3O7P) Rabbit mAb (1:1000, Cell Signaling Technology, #63000); Na,K-ATPase Antibody (1:1000, Cell Signaling Technology, #3010); Integrin alpha 4/CD49D (1:1000, Abcam, Rabbit mAb, #ab81280); Integrin beta 1 (1:1000, Abcam, Rabbit mAb, #ab52971).

Techniques: Injection, Staining, TUNEL Assay, Expressing

Journal: Nature Communications

Article Title: A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy

doi: 10.1038/s41467-023-40996-2

Figure Lengend Snippet: a Schematic illustration of the procedure for evaluation of the antitumor effect and immune responses induced by various treatments in bilateral 4T1 tumor-bearing mice model. The “i.v.” represents “intravenous injection”. The illustration was created with BioRender.com. Plots of b primary tumor volume, c distant tumor volume, d individual tumor growth curve of distant tumor, and e body weight of the bilateral 4T1 tumor-bearing mice post various treatments. Data are presented as mean ± SD ( n = 5 mice). f , g Representative flow cytometry analysis and quantitative data of the population of DC maturation (CD11c + CD80 + CD86 + ) in lymph nodes after various treatments on day 14. Data are presented as mean ± SD ( n = 3 mice). Statistical significance was determined using one-way ANOVA. h Quantitative data of the percentages of CD8 + T cells in primary tumors collected from bilateral 4T1 tumor-bearing mice after various treatments on day 14. Data are presented as mean ± SD ( n = 3 mice). Statistical significance was determined using one-way ANOVA. i , j Representative flow cytometry plots and quantitative data of the percentages of CD8 + T cells in distant tumors collected from bilateral 4T1 tumor-bearing mice after various treatments on day 14. Data are presented as mean ± SD ( n = 3 mice). Statistical significance was determined using one-way ANOVA. Representative flow cytometry data of CD8 + Tem cells (CD44 + and CD62L ‒ ) in spleen, H&E and TUNEL staining of distant tumors in bilateral 4T1 tumor-bearing mice from k “PBS” group and l “M1-MPNPs + L” group on day 14 ( n = 3 mice). Scale bars: 50 μm. Experiment was repeated three times independently with similar results. Source data are provided as a Source Data file.

Article Snippet: Antibodies used: Western blotting: Anti-CD86 (C-terminal) Polyclonal antibody (1:1000, Proteintech, Rabbit mAb, #26903-1-AP); Recombinant Anti-iNOS antibody (1:1000, Abcam, Rabbit mAb, #ab178945); CD47 (D3O7P) Rabbit mAb (1:1000, Cell Signaling Technology, #63000); Na,K-ATPase Antibody (1:1000, Cell Signaling Technology, #3010); Integrin alpha 4/CD49D (1:1000, Abcam, Rabbit mAb, #ab81280); Integrin beta 1 (1:1000, Abcam, Rabbit mAb, #ab52971).

Techniques: Injection, Flow Cytometry, TUNEL Assay, Staining